Newron Pharmaceuticals (NWRN) Stock Overview
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NWRN Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Newron Pharmaceuticals S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 12.10 |
| 52 Week High | CHF 31.85 |
| 52 Week Low | CHF 6.50 |
| Beta | 0.74 |
| 1 Month Change | -14.43% |
| 3 Month Change | -26.40% |
| 1 Year Change | 64.85% |
| 3 Year Change | 181.40% |
| 5 Year Change | 368.09% |
| Change since IPO | -77.21% |
Recent News & Updates
Still A Binary Phase III Bet on Evenamide
Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
Late Stage CNS Pipeline And Patent Protection Will Support Long Term Schizophrenia Opportunity
Catalysts About Newron Pharmaceuticals Newron Pharmaceuticals focuses on developing central nervous system therapies, with a current emphasis on evenamide for schizophrenia. What are the underlying business or industry changes driving this perspective?
Late Stage Schizophrenia Pipeline And Extended Patents Will Transform Long Term Prospects
Catalysts About Newron Pharmaceuticals Newron Pharmaceuticals is a biopharmaceutical company focused on developing evenamide as an add-on therapy for schizophrenia and related central nervous system disorders. What are the underlying business or industry changes driving this perspective?Recent updates
Still A Binary Phase III Bet on Evenamide
Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.Late Stage CNS Pipeline And Patent Protection Will Support Long Term Schizophrenia Opportunity
Catalysts About Newron Pharmaceuticals Newron Pharmaceuticals focuses on developing central nervous system therapies, with a current emphasis on evenamide for schizophrenia. What are the underlying business or industry changes driving this perspective?Late Stage Schizophrenia Pipeline And Extended Patents Will Transform Long Term Prospects
Catalysts About Newron Pharmaceuticals Newron Pharmaceuticals is a biopharmaceutical company focused on developing evenamide as an add-on therapy for schizophrenia and related central nervous system disorders. What are the underlying business or industry changes driving this perspective?Newron Pharmaceuticals S.p.A. (VTX:NWRN) Just Reported And Analysts Have Been Cutting Their Estimates
As you might know, Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) recently reported its annual numbers. It was a moderately...What You Need To Know About The Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analyst Downgrade Today
Today is shaping up negative for Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shareholders, with the analysts delivering...Further Upside For Newron Pharmaceuticals S.p.A. (VTX:NWRN) Shares Could Introduce Price Risks After 26% Bounce
Despite an already strong run, Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shares have been powering on, with a gain of...Newron Pharmaceuticals S.p.A. (VTX:NWRN) Soars 29% But It's A Story Of Risk Vs Reward
Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shares have continued their recent momentum with a 29% gain in the last...Take Care Before Diving Into The Deep End On Newron Pharmaceuticals S.p.A. (VTX:NWRN)
Newron Pharmaceuticals S.p.A.'s ( VTX:NWRN ) price-to-sales (or "P/S") ratio of 3.2x might make it look like a strong...Earnings Miss: Newron Pharmaceuticals S.p.A. Missed EPS By 53% And Analysts Are Revising Their Forecasts
There's been a major selloff in Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shares in the week since it released its...Take Care Before Jumping Onto Newron Pharmaceuticals S.p.A. (VTX:NWRN) Even Though It's 29% Cheaper
Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shareholders won't be pleased to see that the share price has had a very...Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues
When you see that almost half of the companies in the Pharmaceuticals industry in Switzerland have price-to-sales...Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being
Key Insights Newron Pharmaceuticals will host its Annual General Meeting on 17th of April Total pay for CEO Stefan...We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package
The results at Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) have been quite disappointing recently and CEO Stefan Weber...Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns
It is a pleasure to report that the Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) is up 38% in the last quarter. But will...Shareholder Returns
| NWRN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -5.2% | 4.2% | 1.2% |
| 1Y | 64.9% | 24.0% | 7.1% |
Return vs Industry: NWRN exceeded the Swiss Pharmaceuticals industry which returned 24% over the past year.
Return vs Market: NWRN exceeded the Swiss Market which returned 7.1% over the past year.
Price Volatility
| NWRN volatility | |
|---|---|
| NWRN Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.9% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: NWRN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: NWRN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 27 | Stefan Weber | www.newron.com |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.
Newron Pharmaceuticals S.p.A. Fundamentals Summary
| NWRN fundamental statistics | |
|---|---|
| Market cap | CHF 244.26m |
| Earnings (TTM) | -CHF 12.21m |
| Revenue (TTM) | CHF 17.64m |
Is NWRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NWRN income statement (TTM) | |
|---|---|
| Revenue | €19.13m |
| Cost of Revenue | €0 |
| Gross Profit | €19.13m |
| Other Expenses | €32.37m |
| Earnings | -€13.24m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 22, 2026
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 100.00% |
| Net Profit Margin | -69.22% |
| Debt/Equity Ratio | -336.4% |
How did NWRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 18:39 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Newron Pharmaceuticals S.p.A. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jyoti Prakash | Edison Investment Research |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Lucy Codrington | Jefferies LLC |